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Sjogren’s syndrome (SS) is an autoimmune disease, among the most common ones, 
that targets mainly the exocrine glands as well as extra-glandular epithelial tissues. Their 
lymphocytic infiltration leads to manifestations from other organs (e.g., kidneys, lungs, 
liver, or thyroid), apart from sicca symptoms (xerostomia and keratoconjunctivitis). SS is 
more prevalent in women than in men (9:1). Moreover, p.SS patients are in increased risk 
to develop lymphoma. Certain autoantibodies (e.g., antibodies against ribonucleoprotein 
autoantigens Ro-SSA and La-SSB) are ultimate hallmarks for the disease. It was not 
known until recently that culture-independent techniques like next-generation sequencing 
(NGS) facilitate the study of the microbe communities in humans and scientists achieved 
to define the outlines of the microbiome contribution in health and disease. Researchers 
have started to investigate the alterations in diversity of the oral, ocular, or intestinal 
microbiota in SS. Recent studies indicate that dysbiosis may play a significant role in 
SS pathogenesis. At the same time, the cause or effect is not clear yet because the 
dysfunction of salivary glands induces alterations in oral and intestinal microbiome which 
is linked to worsen of symptoms and disease severity. If the human microbiome proves 
to play a key role in pathogenesis and manifestation of SS, the next step could be 
new and promising therapeutic approaches such as probiotics or prebiotics. This mini 
review focuses on the alterations of microbiome of SS patients, their connection with 
immune tolerance and new therapeutic strategies involving diet manipulation toward 
future personalized medicine.
Keywords: Sjogren’s syndrome, microbiome, dysbiosis, probiotics, prebiotics, therapeutic microbiota 
manipulations
KeY MeSSAGeS
•	 Sjogren’s	syndrome	is	a	multifactorial,	autoimmune	disease	still	underdiagnosed	and	undertreated.
•	 All	of	its	pathophysiology	and	etiology	aspects	are	not	fully	elucidated.
•	 Recent	studies	have	strive	to	examine	the	potential	interactions	with	the	human	microbiome	as	
regards	to	all	the	disease	aspects,	exploiting	vital	information	from	other	autoimmune	conditions,	
namely,	IBD,	T1DM,	etc.
•	 Diet	 interventions	and	supplementations	 for	SS	patients	need	 to	be	 thoroughly	examined	and	
researched	 to	 identify	novel	 therapies	and	prevention	measures	 in	 the	context	of	personalized	
medicine.
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inTRODUCTiOn
Sjogren’s	 syndrome	 (SS)	 is	 an	 autoimmune	 disease,	 among	
the	 most	 common	 ones,	 possibly	 as	 common	 as	 rheumatoid	
arthritis	 (RA)	 that	 targets	mainly	 the	 exocrine	 glands	 as	well	
as	extra-glandular	epithelial	tissues.	Lymphocytic	infiltration	of	
salivary	and	lacrimal	glands	leads	to	dysfunction	that	is	becom-
ing	obvious	by	the	emergence	of	“sicca	syndrome”	(dry	eyes–dry	
mouth).	 In	 addition,	 clinical	 symptoms	 could	 derive	 from	
autoimmune	invasion	(so	called	“autoimmune	epithelitis”)	(1)	
in	other	organs,	namely,	kidneys,	lungs,	etc.	It	is	a	heterogenous	
and	 multifactorial	 disease	 involving	 genetic,	 environmental,	
and	 hormonal	 parameters	 that	 may	 occur	 in	 any	 age	 with	 a	
male/female	ratio	1:10	(2).	SS	is	considered	a	benign	condition	
although	 is	 characterized	 by	 high	 incidence	 of	 lymphoma.	
Unfortunately,	it	is	a	disease	with	poor	diagnosis	and	undertreat-
ment	although	the	last	decades	a	lot	of	efforts	have	been	made	
by	 clinicians	 and	 researchers.	The	 gap	 in	 therapeutic	 options	
may	be	filled	by	 the	 recent	advances	 in	microbiome	research.	
Dysbiosis	has	already	been	a	suspect	for	SS’s	pathogenesis	like	
other	 inflammatory	 diseases	 and	 the	 scientific	 community	
examines	now	the	possible	interplay	between	human	microbi-
ome	and	SS	clinical	manifestations	and	severity.	Mouse	models	
of	the	disease	have	been	implicated	a	lot	during	the	last	decades	
although	the	multifactorial	origin	of	pSS	poses	certain	cons	to	
their	usage.	non-obese	diabetic	(NOD)	mice	manifest	not	only	
type	I	diabetes	(T1D)	but	SjS-like	autoimmune	endocrinopathy	
as	well	and	also	present	a	few	hallmark	autoantibodies	like	ANA,	
anti-SSA/Ro,	anti-SSB/La,	anti-a-fodrin,	etc.	(3–5).
Several	 experimental	 approaches	demonstrated	 that	 there	 is	
a	link	between	gut	microbiota	alterations	and	disease	manifesta-
tions,	 severity	and	 treatment	 responsiveness.	For	example,	 it	 is	
now	 known	 that	 gut	 dysbiosis	 with	 a	 low	 relative	 richness	 of	
symbionts	and	high	relative	richness	of	pathobionts	deteriorates	
SS-like	disease	in	mouse	model	and	correlates	with	SS	severity	in	
humans	(6).
Interventions	 targeting	 restoration	 of	 the	 microbiota	 shift	
using	 for	 example	 food	 supplements	 is	 currently	 under	 the	
microscope	to	elucidate	the	effects	on	clinical	status.	Prebiotics	
and	probiotics	are	considered	modern	strategies	for	gut	micro-
biota	 modulation,	 and	 we	 herewith	 provide	 a	 mini	 review	
focused	on	 the	 alterations	of	microbiome	of	 SS	patients,	 their	
microbiome–host	 interactions	 and	 novel	 treatments	 involving	
diet	manipulation	toward	future	personalized	medicine.
SHORT DiGeST in THe CURRenT  
STUDY OF SS
Sjogren’s	 syndrome	a	heterogenous	 and	multifactorial	disease	
involving	 genetic,	 environmental,	 and	 hormonal	 parameters	
that	may	 occur	 in	 any	 age	with	 a	male/female	 ratio	 1:10	 (2).	
When	SS	exists	solely	is	called	primary	SS	to	make	the	distinction	
from	 the	 situation	 of	 secondary	 SS	 when	 another	 autoim-
mune	 disease	 coexist	 or	 preexisted,	 namely,	 systematic	 lupus	
erythematosus	or	RA.	In	the	lymphocytic	infiltration	of	tissues,	
the	 predominant	 characteristic	 figure,	 in	 most	 of	 the	 cases,	
the	outnumbered	T cells	and	in	other	cases	B cells.	The	lateral	
situation	becomes	apparent	with	the	presence	of	certain	autoan-
tibodies	first	Ro/SSA	and	La/SSB	and	second	rheumatoid	factor,	
anti-fodrin	antibodies,	etc.
Despite	 the	 fact	 that	 the	 pathophysiology	 of	 SS	 has	 been	
intensively	studied	it	is	not	completely	elucidated.	It	is	well	estab-
lished	that	genetic	predisposition	and	different	environmental	or	
hormonal	factors	may	well	contribute	and	promote	deregulation	
of	the	glandural	epithelial	cells.	These	potential	triggers	 lead	to	
the	 release	 of	 adhesion	molecules	 and	 chemokines	 like	CD54/
ICAM-1	and	CD40	from	the	epithelial	cells	(7).	These	molecules	
recruit	 plasmacytoid	 dendritic	 cells	 and	 T-lymphocytes	 to	 the	
glands.	Dendritic	cells	release	high	levels	of	IFN-a	which	perpetu-
ates	the	recruitment	and	retention	of	the	T-lymphocytes,	mainly	
CD4+	 resulting	 in	 the	glandular	 infiltration	of	 the	glands,	one	
of	the	highlights	of	the	SS.	The	activated	T-cells	produce	various	
cytokines,	namely,	IFN-γ,	IL-2,	IL-6,	IL-10,	etc.,	 that	are	corre-
lated	to	the	lesions	of	SS	(8).
At	the	same	time,	interferons	promote	the	secretion	of	B-cell	
activating	factor	(BAFF)	from	the	epithelial,	dendritic,	and	T cells.	
It	is	well	depicted	in	certain	studies	an	augmentation	in	BAFF’s	
serum	levels	of	SS	patients	which	is	correlated	to	the	deregulation	
of	B cells.	This	situation	has	as	a	result	the	presence	of	autoantibodies	
like	anti-SSA/Ro,	anti-SSB/La,	etc.	(9,	10).	Genetic	predisposition	
according	to	researchers	implicates	the	major	histocompatibility	
complex	class	II	gene	region,	especially	HLA-DR	and	HLA-DQ	
alleles.	Most	of	the	related	studies	are	devoted	to	specific	genes	for	
proteins	related	to	innate	and	adaptive	immunity	like	PT-PN22W	
variant	(11)	or	TNFAIP3	variant	(12)	trying	to	prove	the	genetic	
background	of	 SS.	 In	 addition,	 a	 lot	 of	 interest	 is	 accumulated	
toward	different	epigenetic	 factors	as	miRNA,	 long	non-coding	
RNA,	and	DNA	methylation	(13–15).
It	 is	 generally	 accepted	 that	 genetics	 in	 tandem	 with	 envi-
ronmental	 factors,	 especially	 viruses	 (chronic	 hepatitis	 virus,	
Epstein–Barr	 virus,	 etc.),	 provokes	 the	 initiation	 of	 a	 cataract	
that	leads	to	inflammation	and	autoimmunity	with	glandural	and	
extra	glandural	manifestations	(16).
Recent	 research	 conducted	 SS	 in	 regard	 to	 symptoms	 and	
diagnosis	are	focused	upon	the	discrimination	of	different	sub-
types	of	pSS	(17),	the	evaluation	of	independent	risk	factors	for	
lymphoma	development	(e.g.,	RF	positivity,	Raynaud’s	phenom-
enon)	(18),	neurological	and	renal	involvement	and	comorbidi-
ties	(e.g.,	cardiovascular	disorders,	depression,	etc.)	(17).
As	regards	treatment	options	the	truth	is	that	scientists	walk	
on	 the	dark	 side	of	 the	moon.	 In	 the	dawn	of	 2017,	Birt	 et  al.	
in	 a	population-based	 study	which	 included	more	 than	10,000	
patients	with	pSS,	 suggested	 that	first	 line	drugs	are	 the	symp-
tomatic	and	immunosuppressive	ones	whereas	there	is	a	lack	of	
biologic	therapies	prescriptions	(19).	According	to	other	studies	
potential	 therapeutic	 interventions	 include	anti-BAFF	antibod-
ies	or	BAFF	antagonists	(e.g.,	Belimumab,	Atacicept,	Briobacept,	
etc.).	 In	 addition,	 anti-CD20	 and	 anti-CD22	 therapy	 results	 to	
B-cell	depletion	 leading	 to	 improvement	 in	SS	 symptoms	 (e.g.,	
rituximab),	methotrexate	as	an	immunosuppressive	drug	as	well	
and	 recently	 interleukin	 targeted	 treatment	 (e.g.,	 IL-6	 tocili-
zumab)	(16,	20–26).	Unfortunately,	all	these	options	still	require	
human	 trials	 to	 prove	 their	 effectiveness	 and	 especially	 in	 pSS	
patients.
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A new ACTOR On STAGe: THe HUMAn 
MiCROBiOMe
During	the	last	decades,	cutting-edge	together	with	the	expan-
sion	of	bioinformatics	 facilitated	 the	 scientists	 to	 elucidate	 the	
commensal,	 symbiotic	 and	 pathogenic	microbial	 communities	
of	 the	 human	 body.	 The	 next	 generation	 sequencing	 (NGS)	
methodologies	 encompass	 the	 16S	 ribosomal	 RNA	 (r	 RNA)	
gene	 sequencing	 and	 metagenomic	 shotgun	 sequencing	 (27).	
The	Human	Microbiome	Project	from	the	National	Institute	of	
Health	in	the	United	States	was	the	most	famous	initiative	that	
characterized	 the	 bacterial	 composition	 in	 different	 body	 sites	
(28,	29)	and	specifically	the	abundance,	diversity,	and	the	features	
of	all	the	microorganisms’	genes.	In	fact,	we	are	more	microbes	
than	humans	as	the	proportion	of	the	microbe	cells	to	human	ones	
is	10	to	1.	The	human	microbiome	is	consisted	of	100	trillion	bac-
teria,	protozoa,	fungi,	and	viruses.	It	is	of	paramount	importance	
contributing	to	health	and	disease	through	numerous	biological	
procedures	as	energy	extraction,	regulation	of	metabolism,	pro-
tection	from	pathogenic	microbes,	production	of	vitamins	and	
last	but	not	least	regulation	of	our	immune	system	(28,	29).	The	
most	abundant	site	of	the	body	is	the	gut	with	500–1,000	species.	
Most	 of	 the	microbes	 belong	 to	 four	major	 phyla:	 Firmicutes,	
Bacteroidetes,	Actinobacteria,	 and	 Proteobacteria	 (30–32)	 and	
actually	 Bacteroidetes	 along	 with	 Firmicutes	 represent	 more	
than	90%	of	 the	whole	 in	 the	gut	 (31,	32).	Presumably,	due	 to	
its	numerous	microbiota	and	significant	metabolic	activity,	 the	
human	intestine	is	described	as	an	“active	organ”	(33).	Data	from	
16S	RNA	gene	and	whole	genome	shotgun	succeeded	to	classify	
Europeans	 to	 three	enterotypes	with	 regard	 to	variation	of	gut	
microbiome	(31,	34).
There	 several	 factors	 which	 affect	 the	 numbers,	 composi-
tion,	 and	 diversity	 of	 intestine	 microbiota	 from	 newborn	 till	
the	 elderly	 such	 as	 gender,	 diet	 habits,	 smoking,	 vaccinations,	
infections,	 age,	 stress,	 etc.	During	 the	first	week	of	 its	 life,	 the	
newborn	 develops	 an	 augmented	 number	 of	 gut	 bacteria	 that	
as	 it	 seems	depends	mainly	not	upon	delivery	mode	but	upon	
mode	of	feeding.	Breast-feeding	offers	greater	counts	of	bacteria	
comparing	to	more	solid	food,	whereas	cesarean	versus	vaginal	
delivery	mode	shows	similar	bacteria	counts	but	from	different	
origin	 (mother’s	 vagina	 versus	 skin	 origin)	 (33,	 35).	 Survey	
studies	depict	that	diversity	and	richness	augment	during	life	up	
to	adulthood	and	then	gradually	reduce	(36).	A	healthy	human	
intestine	microbiome	 is	 characterized	 by	 high	 diversity	 while	
any	 kind	 of	 loss	 of	 diversity	 may	 lead	 to	 dysbiosis,	 a	 critical	
condition	of	disproportion	between	commensal	and	pathogenic	
bacteria.	These	 commensals	 fill	 an	 important	niche	with	 their	
up	or	down	regulation	of	immune	response	and	by	maintaining	
a	 homeostatic	 environment.	As	 a	 result	 of	 these	 observations,	
there	 are	 numerous	 publications	 for	 the	 possible	 interaction	
between	 dysbiosis	 and	 inflammatory	 and	 metabolic	 diseases,	
for	instance,	obesity,	cancer,	asthma,	and	autoimmune	diseases	
as	inflammatory	bowel	disease	(IBD),	Crohn’s	disease,	RA,	etc.	
(36).	Intriguingly,	these	studies	have	failed	up	to	now	to	establish	
a	causative	role	for	the	microbiome	but	mainly	focus	upon	the	
interplay	 between	 pathogenesis,	 clinical	 manifestations,	 and	
disease	prognosis	with	the	microbiome	alterations.
Host	 immunity	 to	 pathogens	 is	 largely	 regulated	 by	 the	
commensal	 microbiota	 as	 numerous	 studies	 have	 shown.	 On	
the	 other	 hand,	 the	 microbiota	 implication	 in	 autoimmune	
response’s	regulation	is	still	a	matter	of	discussion	and	research	
(37).	 Recent	 findings	 describe	 the	 effect	 of	microbiome	 shifts	
toward	 the	 emergence	 of	 autoimmunity.	The	 introduction	 of	
high-throughput	methods	in	microbiome	analysis	like	sequenc-
ing	 of	 16S	 rRNA,	 next-generation	 sequencing	 (NGS),	 and	
metabolomics	offered	 the	opportunity	 for	 large	cohort	 studies	
which	 revealed	 that	 the	 role	 of	 microbiota	 in	 the	 context	 of	
autoimmunity	 could	 be	 “protective,	 neutral,	 or	 provocative”	
as	 Yurkovetskiy	 et  al.	 pointed	 out	 (38).	Microbiota	may	 have	
impact	on	autoimmunity	and	autoimmune	disease	development	
in	different	means.	Direct	effects	of	commensals	include	the	well	
established	molecular	mimicry	 as	 potential	 ligand	 to	 autoim-
munity	through	the	existence	of	non-selective	T cell	receptors	
with	cross-reactivity	to	self-antigens.	In	addition,	many	innate	
immune	sensors	are	activated	by	microbe	components	(patho-
gen-associated	molecular	patterns),	 and	microbial	metabolites	
might	 be	 another	part	 of	 a	 chain	 in	 this	 procedure	 (38).	Diet	
interventions	could	affect	target	organs	like	pancreas	or	neural	
tissue	 by	microbiota	 shifts	 or	 in	 a	 straight	 pathway.	 Relevant	
experiments	 in	 NOD	 mice	 demonstrated	 that	 diet	 changes	
decreased	the	incidence	of	T1D	on	the	if	only	started	from	the	
utero	life	(39).	Sexual	dimorphism,	a	prominent	characteristic	of	
many	autoimmune	diseases,	according	to	recent	studies,	may	be	
attributed	to	a	microbiota	role	in	hormonal	alterations	(40,	41).
All	these	interactions	are	sufficiently	complicated	and	future	
research	in	gender-specific	microbiota	and	its	relations	in	tandem	
with	cautious	explanation	of	experimental	results	will	probably	
enlighten	the	dark	sides	of	the	autoimmune	conditions.
BiDiReCTiOnAL ReLATiOn BeTween 
MiCROBiOMe AnD SS
Having	 considered	 all	 the	 above	 it	 is	 more	 than	 obvious	 the	
accumulating	research	currently	focuses	on	the	contribution	of	
human	microbiome	 to	 systemic	 autoimmune	 diseases	 (SADs).	
Bacteria	 of	 the	 microbiome	 get	 in	 touch	 with	 the	 mucosal	
immune	system	and	after	various	 interactions	can	 lead	 to	dys-
biosis	with	local	inflammation	and	disruption	of	gut	barrier.	As	a	
cataract	numerous	consequences	might	occur,	for	instance,	pro-
inflammatory	 cytokines	 in	 systemic	 circulation,	distant	 impact	
of	inflammation	such	as	joints,	greater	antigen	exposure	with	the	
increase	of	autoantibody	production,	etc.	SADs	are	multifactorial	
diseases	 implicating	genetic	predisposition,	 environmental	 fac-
tors,	hormonal	influences,	and	a	disordered	immune	system	(42).
Studies	have	suggested	that	T	and	B cells	in	the	mucosa	signifi-
cantly	interfere	and	promote	the	immune	homeostasis	working	
in	 two	different	fields,	 harnessing	of	 immune	 response	 against	
beneficial	microbes	and	maintaining	the	wholeness	of	gut	barrier	
(43).	 Some	 bacteria	 from	 the	microbiota	 communities	 present	
unique	abilities	to	affect	and	foster	the	activation	and	polariza-
tion	of	certain	lymphocyte	subsets.	For	instance,	experiments	in	
mice	revealed	that	T	helper	17	(Th17)	are	favored	by	segmented	
filamentous	bacteria	in	small	intestine	resulting	in	autoimmune	
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arthritis	(44,	45).	But	Th17 cells’	functionality	may	present	two	
sides	of	the	same	coinas	they	may	act	either	by	preventing	infec-
tion	or	be	pathogenic	by	secreting	pro-inflammatory	cytokines	
(46–49).	It	 is	still	vague	the	exact	mechanism	that	governs	this	
procedure	of	Th	differentiation.
Another	 lymphocyte	 subpopulation	 that	 comprise	 a	 large	
number	is	the	T regulatory	(Treg)	cells.	Tregs	are	invaluable	for	
their	 contribution	 in	 immune	 tolerance	 to	diet-origin	antigens	
and	gut	microbes.	Studies	concerning	the	magnitude	of	influence	
of	intestine	microbiota	to	the	induction	of	Tregs	are	still	in	their	
infancy.	For	example,	Tregs	are	induced	by	Clostridium	species	in	
intestine	with	anti-inflammatory	performance	(50,	51).
Finally,	a	vital	requirement	 for	 this	beneficial	role	of	micro-
biota	is	its	establishment	early	in	life.	Otherwise,	the	prevalence	
of	invariant	natural	killer	cells	and	the	suppression	of	Tregs	are	
connected	to	colitis	and	asthma	in	mice	(52,	53)	(Figure 1).
Genetic	background	and	environmental	factors	have	not	gain	
much	 attention	 especially	 for	 SS	 patients	 despite	 the	 fact	 that	
scientists	prove	 and	believe	 in	hereditary	 and	 familial	predis-
position	 and	EBV	association	 for	 the	disease	onset  along	with	
increased	production	of	type	I	IFN	(54–56).	It	is	quite	predictable	
the	 fact	 that	 the	main	body	of	 the	 related	 studies	 refers	 to	 the	
saliva	 alterations	 due	 to	 the	 attack	 of	 the	 salivary	 glands.	 As	
early	as	2003,	Almståhl	et al.	observed	 in	SS	patients’	saliva	an	
augmentation	 of	 Candida species	 and	 Streptococcus mutans	
whereas	 Fusobacterium nucleatum	 colony	 forming	 units	 were	
depleted	(57).	Moreover,	de	Paiva	et al.	found	additionally	high	
levels	 of	 Lactobacillus	 spp.	 in	 supragingival	 plaque	 samples,	
Staphylococcus aureus	along	with	Candida albicans	in	oral	mucosa	
and	tongue,	and	a	decrease	in	Leptotrichia	and	Fusobacterium	(6).	
Concerning	the	gut	microbiota	researchers	revealed	depletion	of	
Faecalibacterium,	 Bacteroides,	 Parabacteroides,	 and	 Prevotella	
and	 augmentation	 of	 Escherichia,	 Shigella,	 and	 Streptococcus 
genera	(6).	It	seems	that	only	Szymula	et al.	managed	to	set	the	
hypothesis	in	a	transgenic	murine	model	that	dendritic	cells	with	
a	microbial	protein	like	von	Willebrand	factor	type	A	(or	other	
peptides	 produced	 from	 human	 commensals)	 could	 activate	
T cells	with	a	Ro60	receptor	and	leads	to	autoantibody	production	
(58).	Molecular	mimicry	 as	 a	 possible	mechanism	 for	 autoim-
munity	could	explain	the	microbiome–SS	connection	(58),	and	
deregulated	immune	response	fighting	the	normal	microbiome	
could	be	 considered	as	 a	potential	pathway	 in	SS	pathogenesis	
and	 disease	 perpetuation.	 Regretfully,	 just	 hints	 and	 indirect	
evidences	are	the	only	elements	in	this	puzzle	up	to	now.
It	 is	 generally	 accepted	 the	 pathophysiological	 role	 of	 auto-
reactive	B  cells	 and	Th17 cells	 in	 SS	 and	 the	direct	or	 indirect	
implication	of	the	human	microbiome.
Th17	cells	are	present	in	salivary	glands	of	SS	patients	and	in	
peripheral	 blood	 as	well.	 So	 it	 could	 be	 a	 solid	 hypothesis	 the	
increase	of	this	population	due	to	dysbiosis	leads	to	entering	the	
circulation	 and	 reach	 the	 exocrine	 glands.	 Unfortunately,	 it	 is	
still	unclear	 if	 the	origin	of	 the	Th17 cells	 is	 lamina	propria	of	
the	gut	and	the	pattern	that	gut	immunity	triggers	autoimmune	
procedures	at	distal	sites	(i.e.,	salivary	glands)	(42).
MiCROBiOMe SHiFTS AnD FUTURe 
DieTARY inTeRvenTiOnS in SS
Collectively,	all	the	above	information	has	stressed	on	the	“fight”	
against	dysbiosis	which	is	clearly	implicated	in	the	onset	and	con-
tinuing	of	autoimmunity.	Different	studies	on	SS	have	presented	
indirect	 evidence	 in	 shifts	 of	 oral,	 skin,	 and	 gut	 microbiome	
(58,	59)	but	not	direct	connection	leading	to	the	hypothesis	that	
if	the	microbiome	really	plays	an	important	role	then	novel	treat-
ment	ways	such	as	diet	interventions	and	“functional	food”	could	
offer	an	alternative	to	traditional	immunosuppressive	therapies.	
Dysbiosis	as	a	condition	of	aberrant	function	of	microbiota	that	
leads	 to	 deregulation	 of	 immune	 and	 metabolic	 homeostasis,	
low-grade	 chronic	 inflammation	may	 contribute	 or	 predispose	
to	a	wide	range	of	inflammatory	diseases	such	as	allergy,	asthma,	
autoimmune	diseases,	obesity	and	metabolic	disorders,	cognitive	
and	mental	health	dysfunction,	etc.	(60).	Targeting	dysbiosis	by	
implementing	diet-induced	shifts	in	microbiome	may	affect	the	
development	of	autoimmunity.	Efforts	to	correct	the	malfunction	
of	 the	 disturbed	 gut–barrier	 encompass	 generally	 probiotics,	
prebiotics,	 dietary	 fiber,	 and	 fecal	 microbiota	 transplantation	
depending	on	the	disease.
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Probiotics	are	live	microorganisms	which	when	administered	
in	 adequate	 amounts	 confer	 a	 health	 benefit	 on	 the	 host	 (61).	
Probiotic	microorganisms	 include	 principally	 bacteria	 that	
produce	lactic	acid	as	Lactobacillus	and	Bifidobacterium	genera	
(LAB).	 Their	 use	 is	 mainly	 to	 restore	 the	 microbiota	 imbal-
ance	by	different	mechanisms	that	are	still	under	research	(62)	
even	 though	 there	 are	 plenty	 of	 studies	 that	 demonstrate	 the	
beneficial	 effect	on	allergic	diseases	 (e.g.,	 asthma	and	eczema),	
obesity,	metabolic	syndrome,	gastrointestinal	disorders,	etc.	(60).	
Prebiotics	 are	 non-digestible	 fermentable	 oligosaccharides	 that	
could	alter	 the	composition	and/or	 the	 functionality	of	 the	gut	
flora	 and	 contribute	 to	 the	 increase	 of	 the	 beneficial	 bacteria,	
namely,	Lactobacilli	and	Bifidobacteria	(36,	63,	64).	In	the	same	
manner,	 a	 combination	 of	 pre-	 and	 probiotics	 (symbiotic)	 has	
been	used	(65).
Currently,	researchers	spark	interest	in	the	therapeutic	capa-
bility	 of	 probiotics	 and	 prebiotics	 based	 approaches	 regarding	
autoimmune	diseases.	This	strategy	might	represent	a	more	
natural	 way	 to	 master	 the	 autoimmune	 response	 by	 avoiding	
any	 side	 effects	 of	 immunosuppressive	 drugs.	The	most	 recent	
studies	 focus	 on	 the	 effect	 of	 functional	 food	 (prebiotics	 and	
probiotics)	on	Treg	cells	concerning	autoimmune	disorders	(66).	
Natural	 Treg	 cells	 population	 represents	 the	 cornerstone	 for	
the	 peripheral	 tolerance,	 playing	 a	 crucial	 role	 to	 suppress	 the	
autoreactive	 T-cells	 which	 have	 surpassed	 thymus	 supervision	
and	cancel	any	autoimmune	response.	Any	kind	of	 inadequacy	
of	these	cells	as	regards	the	number	or	activity	seems	to	be	cor-
related	with	different	 autoimmune	disorders,	 for	 instance,	der-
matomyositis	(67),	systemic	lupus	erythematosus	(68),	or	vitiligo	
(69).	Konieczna	et al.	in	2012	revealed	that	certain	probiotics	can	
promote	 the	 induction	 of	Tregs	 in	 patients	with	 inflammatory	
disease	(70).	This	induction	could	restore	the	imbalance	between	
Tregs	 and	 effector	 CD8+	 CD4+	 Tcells	 (in	 greater	 number	 in	
autoimmunity)	 resulting	 in	 immune	 homeostasis	 (decrease	 of	
pro-inflammatory	 factors,	 augmentation	 of	 anti-inflammatory	
factors,	 increase	 in	 number	 and	 activity	 of	 Tregs,	 decrease	 of	
cytotoxicity,	etc.)	(69).	In	a	similar	manner,	prebiotics	and	their	
metabolites	in	recent	reports	seem	to	compel	to	homeostasis	by	
different	mechanisms	such	as	short	chain	fatty	acids	induction	of	
Tregs,	by	prostaglandin	E2,	etc.	(69).
Indeed,	there	is	a	bulk	of	evidence	that	there	are	certain	bacteria	
which	could	affect	the	induction	of	Treg	cells	in	the	intestine	and	
prevent	Th17	expansion	like	Bacteroides fragilis	and	Clostridium	
strains	 in	 experimental	 colitis,	 T1DM	 and	 IBD.	These	 results	
could	be	valuable	lessons	for	future	studies	in	animal	and	humans	
regarding	 SS	 and	 the	 shaping	 of	 the	 microbiota	 to	 suppress	
autoimmunity.	Given	the	crucial	role	of	the	benefic	bacteria	and	
the	 possible	 diet	 interventions	 using	 probiotics	 and	 prebiotics,	
SS	 patients	 could	 ameliorate	 disease	 severity	 and	 prediction.	
The	paucity	of	studies	concerning	specifically	this	entity,	either	
animal	or	human	studies	reveals	the	magnitude	of	the	problem.	
Knowledge	 from	 other	 autoimmune	 disorders	 could	 facilitate	
the	assumption	that	microbiome	manipulation	may	alleviate	the	
disease	burden.
COnCLUSiOn
Sjogren’s	 syndrome	 as	 a	 common,	 multifactorial	 autoimmune	
disorder	 remains	 till	 now	 mostly	 underdiagnosed	 and	 under-
treated.	At	the	same	time	as	the	latest	breakthroughs	in	culture-
independent	techniques	of	studying	human	microbiome	revealed	
its	 possible	 connection	 with	 SS	 pathogenesis,	 onset,	 severity,	
and	 treatment,	 scientific	community	 sparked	off	a	new	field	of	
interest.	Having	considered	pioneer	research	as	regards	autoim-
munity	 and	microbiota	 in	 general	 and	 the	profound	 contribu-
tion	of	dysbiosis,	 future	efforts	possibly	would	be	focused	first,	
on	 the	 determination	 whether	 the	 reduced/altered	 microbial	
diversity	 is	causal.	Second,	 it	 seems	essential	 to	define	 the	pre-
cise	 mechanisms	 of	 microbiome	 shifts’	 occurrence	 driving	 by	
specific	bacteria	as	well	the	exact	subpopulation	of	the	patients	
that	potential	manipulations	would	be	truly	auspicious	complied	
with	personalized	medicine.	The	intricate	knowledge	of	human	
microbiota	 with	 the	 positive,	 negative	 and	 neutral	 bacteria	 in	
tandem	with	their	resilience	and	stability	(71)	on	one	hand	and	
specific	markers	 for	 the	 efficiency	 of	 the	 interventions	 on	 the	
other,	 would	 give	 prominence	 and	 real	 value	 to	 the	 outcome	
of	 a	microbiome-centered	 treatment	 strategy.	 Functional	 food,	
namely,	prebiotics	and	probiotics	offer	a	very	promising	 future	
concerning	SS	therapies	with	diet	interventions	and	may	prove	to	
be	the	ultimate	immunomodulatory	factors	to	suppress	autoim-
munity.	The	very	 encouraging	 results	 of	Zamani	 et  al.	 in	 2016	
(72)	who	demonstrated	the	beneficial	effects	of	8 weeks	probiotic	
supplementation	in	RA	patients	on	their	clinical	and	metabolic	
status,	might	be	only	the	start	of	personalized	manipulations	for	
SS	and	other	autoimmune	entities,	to	shift	their	microbiome	from	
disease	to	health.
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